Skip to main content

Anixa Biosciences Inc

corporate_fare Company Profile

Anixa Biosciences Inc

ANIX·NASDAQ·Life Sciences·CIK 0000715446

Anixa Biosciences, Inc. is a biotechnology company that develops therapies and vaccines for critical unmet needs in oncology. The company's therapeutics program focuses on liraltagene autoleucel ("lira-cel"), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell ("CAR-T") technology. This therapy is initially focused on treating ovarian cancer and is being developed by its subsidiary, Certainty Therapeutics, Inc. ("Certainty"). Anixa's vaccine programs include a vaccine against breast cancer, a vaccine against ovarian cancer, and a vaccine discovery program. This discovery program uses the same mechanism as the breast and ovarian cancer vaccines to develop additional cancer vaccines for intractable cancers, including high incidence malignancies in lung, colon, and prostate. Certainty, Anixa's subsidiary, develops immunotherapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license from The Wistar Institute ("Wistar") for intellectual property related to Wistar's chimeric endocrine receptor targeted therapy technology. While the initial focus is on ovarian cancer, the company may also pursue applications of this technology for other solid tumors. The license agreement requires Certainty to make cash and equity payments to Wistar upon achieving specific development milestones. Certainty initially issued Wistar shares of its common stock equal to five percent (5%) of Certainty's common stock. Due to company funding, Wistar's equity stake in Certainty was 4.1% as of October 31, 2025. Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. ("Moffitt"), has started human clinical testing of lira-cel for ovarian cancer.

Anixa Biosciences Inc (NASDAQ:ANIX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 15 items for ANIX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 15 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for ANIX spans 10-Q, 8-K, 10-K, SCHEDULE 13D/A.

Recent high-impact activity:

  • Fifth CAR-T Cohort Dosed; Four Ovarian Cancer Patients Survive Beyond One Year
  • Anixa CAR-T Shows First Stable Disease at 3 Months in Ovarian Cancer
  • Australian Patent Acceptance Expands Breast Cancer Vaccine IP to Key Market
  • Anixa Biosciences Secures First Korean Patent for Breast Cancer Vaccine, Extending Protection to 2040
  • Anixa Biosciences Reports Improved Q3 Net Loss of $2.52M, $13.7M Cash Extends Runway

Financial Snapshot

Fiscal year ended October 31, 2025
Net Income
-$10.93M
Diluted EPS
-$0.34
Op. Cash Flow
-$7.17M
Operating Income
-$11.7M
Cash & Equivalents
$1.24M
Debt / Equity
0.00×
Shares Outstanding
33.01M sh
Source: 10-K · filed 2026-01-12 · accession 0001493152-26-001845

Short Interest & Short Volume

8.40 days to cover

FINRA reported short interest of 1,628,481 shares in ANIX as of the October 30, 2026 settlement, a 2.0% decrease from the prior period — about 8.4 days to cover at its recent average daily volume. On November 20, 2026, 72.8% of ANIX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,628,481 shares as of October 30, 2026
Change vs prior period▼ 2.0%
Days to cover8.40 at avg daily volume of 193,792
Daily short volume (FINRA facilities)72.8% of 247,593 shares on November 20, 2026
5-day average short volume64.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$2.44
52-week range · as of 2026-06-10 $2.35 – $5.46
Market cap
$84.82M
Volume
355.1K (1.8× avg)
3-mo avg 200.9K
Live data · 2026-11-21 13:51 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ANIX - Latest Insights

ANIX
Oct 26, 2026, 8:30 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $2.99
Real-time Price: $2.44 info
Change: -$0.550 (-18%) info
Market Cap: $84.824M info
ANIX
Oct 05, 2026, 8:16 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.99
Real-time Price: $2.44 info
Change: -$0.550 (-18%) info
Market Cap: $84.824M info
ANIX
Jul 14, 2026, 8:33 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $3.02
Real-time Price: $2.44 info
Change: -$0.582 (-19%) info
Market Cap: $84.824M info
ANIX
Jun 29, 2026, 8:45 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $2.79
Real-time Price: $2.44 info
Change: -$0.3532 (-13%) info
Market Cap: $84.824M info
ANIX
Jun 10, 2026, 4:21 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.36
Real-time Price: $2.44 info
Change: +$0.080 (+3%) info
Market Cap: $84.824M info
ANIX
Jun 10, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.36
Real-time Price: $2.44 info
Change: +$0.080 (+3%) info
Market Cap: $84.824M info
ANIX
Jun 01, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $2.68
Real-time Price: $2.44 info
Change: -$0.2426 (-9%) info
Market Cap: $84.824M info
ANIX
May 11, 2026, 9:19 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.99
Real-time Price: $2.44 info
Change: -$0.550 (-18%) info
Market Cap: $84.824M info
ANIX
Apr 01, 2026, 9:16 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.59
Real-time Price: $2.44 info
Change: -$0.151 (-6%) info
Market Cap: $84.824M info
ANIX
Mar 11, 2026, 5:03 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.06
Real-time Price: $2.44 info
Change: -$0.620 (-20%) info
Market Cap: $84.824M info
ANIX
Mar 09, 2026, 4:21 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.98
Real-time Price: $2.44 info
Change: -$0.540 (-18%) info
Market Cap: $84.824M info
ANIX
Mar 09, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.98
Real-time Price: $2.44 info
Change: -$0.540 (-18%) info
Market Cap: $84.824M info
ANIX
Feb 09, 2026, 8:02 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.06
Real-time Price: $2.44 info
Change: -$0.620 (-20%) info
Market Cap: $84.824M info
ANIX
Jan 12, 2026, 4:01 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $3.16
Real-time Price: $2.44 info
Change: -$0.720 (-23%) info
Market Cap: $84.824M info
ANIX
Jan 06, 2026, 7:48 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $3.60
Real-time Price: $2.44 info
Change: -$1.16 (-32%) info
Market Cap: $84.824M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets